Skip Navigation


Annals of Oncology Advance Access originally published online on September 16, 2009
Annals of Oncology 2009 20(12):2022; doi:10.1093/annonc/mdp461
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/12/2022    most recent
mdp461v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lord, S. R.
Right arrow Articles by Seymour, M. T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lord, S. R.
Right arrow Articles by Seymour, M. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Are we representing the true population in oncology trials?

The first 10% of the full text of this article appears below.

We thank Kang et al. [1] for their trial ML17032 published in the recent issue of Annals of Oncology. This confirmed the noninferiority of capecitabine to infusional 5-fluorouracil as part of palliative combination . . . [Full Text of this Article]

S. R. Lord1,*, P. S. Hall2 and M. T. Seymour1

1 St James's Institute of Oncology
2 University of Leeds, Leeds, UK

* (E-mail: s.r.lord@leeds.ac.uk)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?